LithuaniaTuberculosis profile
Population  2015 2.9 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.23 (0.23–0.23) 7.9 (7.8–8)
Mortality (HIV+TB only) <0.01 (<0.01–0.039) 0.27 (0–1.3)
Incidence  (includes HIV+TB) 1.6 (1.4–1.8) 56 (48–64)
Incidence (HIV+TB only) 0.059 (0.049–0.069) 2 (1.7–2.4)
Incidence (MDR/RR-TB)** 0.36 (0.3–0.41) 13 (10–14)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.076 (0.052–0.1) 0.42 (0.25–0.6) 0.5 (0.3–0.7)
Males 0.076 (0.056–0.097) 1 (0.81–1.3) 1.1 (0.86–1.3)
Total 0.15 (0.12–0.18) 1.5 (1.3–1.6) 1.6 (1.4–1.8)
TB case notifications, 2015  
Total cases notified 1 507
Total new and relapse 1 395
          - % tested with rapid diagnostics at time of diagnosis 0%
          - % with known HIV status 71%
          - % pulmonary 90%
          - % bacteriologically confirmed among pulmonary 85%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.15 (0.12–0.17)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 37 4%
          - on antiretroviral therapy    
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  270
(240–300)
Estimated % of TB cases with MDR/RR-TB 12% (10–15) 47% (41–53)  
% notified tested for rifampicin resistance 76% 100% 1 221
MDR/RR-TB cases tested for resistance to second-line drugs   248
Laboratory-confirmed cases MDR/RR-TB: 248, XDR-TB: 59
Patients started on treatment **** MDR/RR-TB: 248, XDR-TB: 59
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 81% 1 282
Previously treated cases, excluding relapse, registered in 2014 46% 46
HIV-positive TB cases, all types, registered in 2014 72% 25
MDR/RR-TB cases started on second-line treatment in 2013 40% 227
XDR-TB cases started on second-line treatment in 2013 0% 47
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
85% (63–100)
TB financing, 2016  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-08 Data: www.who.int/tb/data